Antiallergic Composition

An antiallergic composition with Agrimol B from Agrimonia pilosa addresses the lack of effective treatments for type I allergies by suppressing mast cell and basophil degranulation, offering relief from allergic symptoms.

JP7592939B2Active Publication Date: 2024-12-03FUAN KERU
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2020206619
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-12-14
Publication Date
2024-12-03
Estimated Expiration
2040-12-14

AI Technical Summary

Technical Problem

Current treatments for type I allergies, such as atopic dermatitis and bronchial asthma, lack effective therapeutic drugs, and existing substances and extracts do not adequately inhibit mast cell and basophil degranulation.

Method used

An antiallergic composition containing Agrimol B, derived from the plant Agrimonia pilosa, is formulated to suppress the degranulation reaction of mast cells and basophils.

Benefits of technology

The composition effectively inhibits the degranulation reaction of granulocytes, providing relief from type I allergic symptoms by reducing the release of inflammatory mediators.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592939000002
    Figure 0007592939000002
  • Figure 0007592939000001
    Figure 0007592939000001
Patent Text Reader

Abstract

To provide a novel antiallergic composition.SOLUTION: An antiallergic composition contains Agrimol B as an active ingredient.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antiallergic composition. [Background technology]

[0002] Various allergies such as hay fever, food allergies, bronchial asthma, and atopic dermatitis are becoming problems. Allergies are classified into four types, type I, type II, type III, and type IV, depending on the type of allergic reaction. Among them, type I is called the immediate type, in which a large amount of IgE antibodies produced by the invasion of an allergen binds to mast cells or basophils, and when an antigen binds to these again, chemical mediators such as histamine and leukotriene are secreted (degranulated), resulting in the development of allergic symptoms. These cause a severe inflammatory reaction in the body, which manifests as various symptoms. This type I allergy is widely recognized as a common disease, including the above-mentioned atopic dermatitis, bronchial asthma, allergic rhinitis, food allergies, hay fever, etc. However, there are currently few effective treatments, and the first choice for treating type I allergies is symptomatic treatment with anti-inflammatory drugs such as anti-inflammatory drugs and steroid preparations.

[0003] In recent years, many substances that suppress the degranulation reaction of mast cells and compositions containing natural extracts have been proposed for the treatment or amelioration of such type I allergies. Patent Document 1 describes an agent for inhibiting degranulation of mast cells or basophils, which contains p-coumaric acid as an active ingredient. Patent Document 2 discloses an agent for inhibiting degranulation of mast cells or basophils, which contains, as an active ingredient, a decomposed extract of bagasse, which is the residue from sugarcane molasses extraction. Patent Document 3 describes that a polar solvent extract obtained by extracting the fruits or seeds of guarana (Paullinia cupana Kunth.) using a polar solvent has an inhibitory effect on basophil cell degranulation, an inhibitory effect on mast cell degranulation, and an inhibitory effect on β-hexosaminidase release. In addition to these prior art techniques, attempts have been made to utilize various substances and extracts that inhibit the degranulation of mast cells and exert anti-allergic effects, but the current situation is that none that exert a desirable effect have yet been offered on the market.

[0004] Meanwhile, plant extracts are currently being used for various medical purposes, and among them, agrimony extract has been attracting attention in recent years. Agrimonia pilosa (scientific name: Agrimonia pilosa) is a perennial plant of the Rosaceae family, used in herbal medicine. Its herbal name is Senkakusou. The stems and leaves of the aboveground part of Agrimonia in flowering season contain essential oils and tannins, the main component of which is known to have an astringent effect that tightens cell tissue. In addition, an aqueous extract boiled in water is said to have a choleretic effect that helps the gallbladder function. The roots are known to contain tannins as well as phenolic glycosides, agrimonolide, phytosterol, vanillic acid, taxifolin, etc.

[0005] Various pharmacological effects of an extract of agrimony are known. Patent Document 4 describes a nerve activating composition containing an extract of agrimony as an active ingredient. Patent Document 5 describes a skin whitening agent, an anti-aging agent, and a skin cosmetic agent that contain an extract of agrimony. Patent Document 6 describes an α-glucosidase inhibitor containing an extract of agrimony. Patent Document 7 describes an external skin preparation and an allergen inactivator that contain an extract of agrimony as an active ingredient. Patent Document 8 describes that a 70% ethyl alcohol extract of agrimony is useful as an arachidonic acid metabolism inhibitor. In an in vitro test using a rat basophilic leukemia cell line (RBL-1), this extract suppressed the production of leukotriene C, an inflammation-causing substance. 4 It has been reported that it has an inhibitory effect on the production of [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2019-127455 A [Patent Document 2] JP 2019-210271 A [Patent Document 3] JP 2010-70531 A [Patent Document 4] JP 2018-8888 A [Patent Document 5] JP 2010-65008 A [Patent Document 6] JP 2006-16388 A [Patent Document 7] JP 2008-174529 A [Patent Document 8] Japanese Patent Application Publication No. 08-176003 [Patent Document 9] Japanese Patent Application Publication No. 11-335256 Summary of the Invention [Problem to be solved by the invention]

[0007] In the course of studying the degranulation of granulocytes such as mast cells and basophils in blood, the present inventors screened various plant extracts and found that a specific extract of agrimony has a strong effect of controlling the degranulation reaction of mast cells and basophils. They also found that Agrimole B contained in the agrimony extract has this effect. They also found that this specific extract of agrimony and Agrimole B are useful for treating type I allergy, and thus made the present invention. That is, an objective of the present invention is to provide a new composition for improving type I allergy. [Means for solving the problem]

[0008] That is, the present invention is configured as follows. (1) An anti-allergic composition containing Agrimole B as an active ingredient. (2) An anti-allergic composition containing a plant extract containing Agrimole B as an active ingredient, wherein the plant extract containing Agrimole B contains at least 0.4% by mass of Agrimole B. (3) The anti-allergic composition according to (2), wherein the plant containing Agrimole B is Agrimony. Effect of the Invention

[0009] The present invention provides an antiallergic composition. Furthermore, the antiallergic composition provided by the present invention can treat type I allergic symptoms by inhibiting the degranulation reaction of granulocyte cells such as mast cells and basophils. [Brief description of the drawings]

[0010] [Figure 1] 1 is a graph showing the results of a test conducted in an embodiment to measure the anti-allergic effects of concentrated agrimony extract and Agrimole B. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] In this specification, the term "composition" refers to medicines, quasi-drugs, and foods. In addition, in the present specification, the term "agrimony extract" refers to an extract obtained by extracting arimony with ethyl alcohol or aqueous ethyl alcohol that contains water. Furthermore, the extract obtained by washing the above-mentioned agrimony extract with 0 to 40% ethyl alcohol to remove 0 to 40% ethyl alcohol soluble components is referred to as a "concentrated agrimony extract" in the present specification.

[0012] Agrimonia pilosa (scientific name: Agrimonia pilosa) is a perennial plant of the genus Agrimonia in the family Rosaceae, and grows naturally on forest edges, in fields, and by roadsides in Honshu, Shikoku, Kyushu, and other areas. It is also known as dragon-tooth grass. In the present invention, the dried Agrimonia pilosa that is commercially available as a raw material for Chinese herbal medicines, folk remedies, and health foods (herbal tea) can be used. The dried whole plant is commercially available under the herbal name Senkakusou. Furthermore, the whole plant, either naturally growing or cultivated, may be collected and naturally or heat-dried and then used. The agrimony is cut into thin strips and immersed in about 10 times the amount of water or 0-99.5% (v / v) ethyl alcohol, preferably 1-50% ethyl alcohol, particularly preferably 5-10% ethyl alcohol, for 3-5 days to extract at room temperature, or extracted at 50-80°C for 5-24 hours using a reflux condenser, and then filtered to recover an agrimony extract. Water and ethyl alcohol are removed from the extract using a reduced pressure vacuum drying device such as a rotary evaporator, or a freeze-drying device, to obtain an agrimony extract. In the present specification, the agrimony extract is also referred to as agrimony extract. This agrimony extract (solid agrimony extract) is washed with 0 to 40% ethanol, particularly preferably with 10 to 30% ethanol, and the 0 to 40% ethanol soluble components are removed by means of filtration or the like. The filtration residue is then subjected to a reduced pressure vacuum drying apparatus such as a rotary evaporator or a freeze-drying apparatus to remove water and ethyl alcohol, thereby obtaining a concentrated agrimony extract. The concentrated agrimony extract can be redissolved in 50 to 99.5% ethanol, particularly preferably 70 to 90% ethanol, and then the excipients used in formulation are added and freeze-dried to obtain a powder composition containing the concentrated agrimony extract of the desired concentration.

[0013] The above-mentioned agrimony extract and concentrated agrimony extract contain Agrimole B. Agrimol B is a compound identified by the following chemical formula 1.

[0014] [ka]

[0015] Agrimol B can be synthesized using phloroglucinol as a starting material, for example, by the method described in Acta Pharmaceutica Sinica 1989, 24(6): pp. 431-437, or the method disclosed in Patent Document 8.

[0016] In addition, there are two types of Agrimol B that can be obtained by synthesis: (S)-(+)-Agrimol B and its optical isomer, (R)-(-)-Agrimol B. In this specification, "Agrimol B" may refer to a single compound consisting of one of these types, or a mixture consisting of two types.

[0017] Agrimole B obtained by chemical synthesis or by extraction, separation and purification from natural products is used in the antiallergic composition of the present invention. Specifically, plant extracts, crude products and the like containing Agrimole at a certain concentration obtained when extracting, separating and purifying Agrimole B from the above-mentioned natural products can be used in the antiallergic composition of the present invention.

[0018] The antiallergic composition containing Agrimole B or a plant extract containing Agrimole B as an active ingredient can be administered to animals and humans as a pharmaceutical composition with Agrimole B or the extract as is, or together with a conventional pharmaceutical formulation carrier. The dosage form of the pharmaceutical composition is not particularly limited and may be appropriately selected as needed. For example, oral preparations such as tablets, capsules, granules, fine granules, and powders, and parenteral preparations such as injections and suppositories can be included. The dosage of oral preparations is usually formulated to contain 1 to 1000 mg of Agrimole B in terms of the dry mass of the extract for adults, and it is appropriate to take this in several divided doses per day. When it is made into a food product, Agrimole B or an Agrimole B-containing plant extract can be dispersed in an appropriate diluting agent and then mixed with food ingredients to obtain a desired form. When it is added to food, it is mixed so that Agrimole B is contained at 1 to 1000 mg per 100 g of food.

[0019] In the present invention, oral preparations such as tablets, capsules, granules, fine granules, and powders containing Agrimole B or a plant extract containing Agrimole B can be prepared according to conventional methods using excipients such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, and inorganic salts. In addition to the composition of the present invention, oral preparations can appropriately contain binders, disintegrants, surfactants, lubricants, flow enhancers, flavorings, colorants, and flavors.

[0020] The following substances can be used as ingredients to be blended with Agrimole B or a plant extract containing Agrimole B. Examples of binders include starch, dextrin, gum arabic, gelatin, hydroxypropyl starch, sodium methylcellulose, hydroxypropyl cellulose, crystalline cellulose, ethyl cellulose, polyvinylpyrrolidone, and macrogol. Examples of disintegrants include starch, hydroxypropyl starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose, and low-substituted hydroxypropyl cellulose. Examples of surfactants include sodium lauryl sulfate, soybean lecithin, sucrose fatty acid ester, and polyoxyethylene sorbitan fatty acid ester. Examples of lubricants include talc, waxes, hydrogenated vegetable oil, sucrose fatty acid ester, magnesium stearate, calcium stearate, aluminum stearate, and polyethylene glycol. Examples of flow promoters include light anhydrous silicic acid, dried aluminum hydroxide gel, synthetic aluminum silicate, and magnesium silicate. The present invention will be described in further detail below with reference to test examples which confirmed the effects of the composition of the present invention. EXAMPLES

[0021] <Test on the degranulation inhibitory effect of Agrimole B or Agrimony extract on mast cells> 1. Test Method (1) Preparation of test samples Preparation of agrimony extract and concentrated agrimony extract 100g of agrimony (Sengakuso, Fukuda Ryu Co., Ltd.) was mixed with 10 times the amount of 90% ethyl alcohol (1 kg) and reflux extraction was repeated twice. After completion, solid-liquid separation was performed to obtain an extract. The obtained extract was treated with activated charcoal and filtered through diatomaceous earth in the usual manner, then concentrated and freeze-dried to obtain a crude extract (solid amount 9.28g, yield 9.28% (vs. raw material)). This crude extract was used in this test as "Agrimony Extract (AP)". 8.51 g of this dried agrimony extract was dissolved and suspended (10% solids) in a 20% ethyl alcohol solution heated to 60°C, and the residue was recovered by diatomaceous earth filtration in a conventional manner. The residue was again dissolved in 90% ethyl alcohol, and filtered through diatomaceous earth in a conventional manner, and then concentrated and freeze-dried again to obtain a concentrate (0.59 g solids, 6.93% yield (relative to agrimony extract)). This is called concentrated agrimony extract (AP(D)). This concentrated agrimony extract is obtained by removing 20% ​​ethyl alcohol soluble components from agrimony extract (AP) to concentrate fat-soluble components including Agrimole B.

[0022] Determination of the content of Agrimole B in agrimony extract and concentrated agrimony extract The content of Agrimole B in the test samples used in this example was measured by a conventional method, and was found to be 0.036% by mass in the agrimony extract and 0.447% by mass in the concentrated agrimony extract. The content of Agrimole B in the test samples used in this example was measured by HPLC under the following conditions. Column: Wakosil-ll5C18 AR 4.6mm x 150mm Mobile phase: distilled water: acetonitrile: phosphoric acid = 100:900:1 Flow rate: 1mL / min Detection: UV288nm Injection volume: 10μL

[0023] Agrimole B Agrimol B (Biorbyt) was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM to prepare a stock solution. This stock solution was used in the following studies.

[0024] (2) Test method The procedure was as follows: 1)Cell culture Basophilic mast cell line RBL2H3 cells (RIKEN JCRB0023 RBL-2H3) established from Wistar rat-derived leukemia cells were cultured at a cell density of 3 × 10 4 The cells were seeded at 100 cells / well in a 96-well plate and cultured for 24 hours using DMEM (high glucose: Invitrogen) as the culture medium.

[0025] 2) IgE antibody binding to cells After removing the culture supernatant, the medium was replaced with a new one, and 100 μl of anti-DNP-IgE antibody (Sigma-Aldrich) was added (final concentration: 500 ng / ml). After further culturing for 2 hours, the cells were harvested. The harvested cells were then stored in Modified Tyrode (MT) buffer (composition: 137 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 6H 2 The plate was washed twice with 200 μl / well of 0, 5.6 mM glucose, 20 mM HEPES, 0.1% BSA, pH 7.3.

[0026] 3) Addition of Agrimole B, agrimony extract, and concentrated agrimony extract 100 μl of the sample dissolved in MT buffer was added and reacted for 10 minutes. The final concentrations of Agrimole B were adjusted to 2.5, 5, and 10 μM, the final concentrations of the Agrimony extract to 12.5, 25, and 50 μg / ml, and the final concentrations of the concentrated Agrimony extract to 12.5, 25, and 50 μg / ml. As a positive control (degranulation inhibitor), 100 μl of Wortmannin (Funakoshi Corporation, hereinafter referred to as "Wort") similarly dissolved in MT buffer was added to a final concentration of 100 nM, and the mixture was allowed to react for 10 minutes. Furthermore, a control was prepared by adding MT buffer containing no sample and reacting in the same manner. Each sample was added and incubated for 3 hours.

[0027] 4) Measurement of degranulation reaction (measurement of β-hexosaminidase activity) After cooling the culture plate on ice for 10 minutes, 100 μl (total amount) of the culture supernatant was transferred to a multiwell plate. The cells were lysed with 100 μl / well of MT buffer containing 0.1% Triton X-100 to obtain a cell lysate. To the culture supernatant and cell lysate, 100 μl / well of 3.3 mM p-Nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside (FUJIFILM Wako Pure Chemical Industries, Ltd.) dissolved in 100 mM citric acid buffer (pH 4.5) was added. After reacting at 37°C for 25 minutes, 100 µl / well of 2M glycine buffer was added to stop the reaction, and the absorbance at 405 nm was then measured using a plate reader.

[0028] 5) Formula for calculating β-hexosaminidase release rate (degranulation rate) The release rate of β-hexosaminidase for each sample was calculated using the following formula. This release rate indicates the degree of mast cell degranulation by IgE. The smaller this value, the stronger the anti-allergic effect. β-hexosaminidase release rate (degranulation rate) = (culture supernatant of IgE-added cells - culture supernatant of IgE-free cells) a ) / (IgE-added cell culture supernatant + IgE-added cell lysate b ) a: Difference in the amount (activity) of β-hexosaminidase spontaneously released without IgE binding from the culture supernatants of each group b: The sum of the amount (activity) of β-hexosaminidase in the medium and in the cells

[0029] 6) Statistical analysis The degranulation rate of each test sample was calculated by average value and standard deviation, and MT buffer not containing the sample was added and reacted in the same manner. The results were compared with the control (Cont) by Dunnett's test for significance. The significance level was set at p<0.05(*) and p<0.01(**).

[0030] 2. Test Results The measurement results are shown in Figure 1. In the control group, IgE caused mast cell degranulation rate of 16%. On the other hand, Agrimole B inhibited degranulation in a concentration-dependent manner, with the degranulation rate of 10.21% at 2.5μM, 7.37% at 5μM, and 5.29% at 10μM, showing a remarkable inhibitory effect. Concentrated agrimony extract also inhibited degranulation in a concentration-dependent manner, with the degranulation rate of 15.49% at 12.5μg / ml, 14.24% at 25μg / ml, and 12.15% at 50μg / ml. Therefore, it was considered that Agrimole B and concentrated Agrimony extract could be used as an effective anti-allergic composition since they inhibit the degranulation reaction induced by IgE. As shown in FIG. 1, the extract of Agrimony (AP) had no effect of suppressing mast cell degranulation, and degranulation was significantly increased at AP concentrations of 25 μg / ml and 50 μg / ml. Based on the above degranulation rate measurement results for agrimony extract and concentrated agrimony extract, it was considered that the content of Agrimole B in the extract is 0.4 mass% or more per total dry matter in order to exert an anti-allergic effect.

Claims

[Claim 1] An anti-allergic composition containing only Agrimole B as an active ingredient.

Citation Information

Patent Citations

  • Arachidonic acid metabolism inhibitor

    JP1996176003A

  • Skin cosmetic

    JP1999335256A

  • alpha-GLUCOSIDASE INHIBITOR

    JP2006016388A

  • Allergen inactivating agent, skin care preparation containing the same and allergen inactivating product

    JP2008174526A

  • Allergen inactivating agent, skin care preparation containing the same and allergen inactivating product

    JP2008174529A